Liver transplantation for colorectal liver metastases: revisiting the concept

被引:74
作者
Foss, Aksel [1 ,2 ]
Adam, Rene [3 ,4 ]
Dueland, Svein [5 ]
机构
[1] Univ Oslo, Rikshosp, Oslo Univ Hosp, Div Surg,Sect Transplantat,Dept Transplantat, N-0027 Oslo, Norway
[2] Univ Oslo, Rikshosp, Oslo Univ Hosp, Inst Surg Res, N-0027 Oslo, Norway
[3] Hop Paul Brousse, AP HP, Ctr Hepatobiliaire, Villejuif, France
[4] ELTR, Paris, France
[5] Radiumhosp, Oslo Univ Hosp, Dept Oncol, Oslo, Norway
关键词
colorectal cancer; liver transplantation; REGULATORY T-CELLS; RADIOFREQUENCY ABLATION; HEPATIC RESECTION; UNITED-STATES; PHASE-II; SURGERY; CANCER; IMMUNOSUPPRESSION; RETRANSPLANTATION; RECURRENCE;
D O I
10.1111/j.1432-2277.2010.01097.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
P>Liver transplantation (Lt) for colorectal cancer (CRC) liver metastases is no more considered due to the poor outcome observed up to the 1990s. According to the European Liver Transplant Registry (ELTR), 1- and 5-year patient survival following Lt for CRC liver metastases performed prior to 1995 was 62% and 18%, respectively. However, 44% of graft loss or patient deaths were not related to tumor recurrence. Over the last 20 years there has been dramatic progress in patient survival after Lt, thus it could be anticipated that survival after Lt for CRC secondaries today would exceed from far, the outcome of the past experience. By utilizing new imaging techniques for proper patient selection, modern chemotherapy and aggressive multimodal treatment against metastases, long term survivors and even cure could be expected. Preliminary data from a pilot study show an overall survival rate of 94% after a median follow up of 25 months. While long term survival after the first Lt is 80% all indications confounded, 5-year survival after repeat Lt is no more than 50% to 55%. If patients transplanted for CRC secondaries can reach the latter survival rate, it could be difficult to discriminate them in the liver allocation system and live donation could be an option.
引用
收藏
页码:679 / 685
页数:7
相关论文
共 57 条
[1]  
AASERUD M, 2007, 23 KUNNSK
[2]  
Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71
[3]   Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases [J].
Abdel-Misih, Sherif Raafat Zikry ;
Schmidt, Carl R. ;
Bloomston, Paul Mark .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2009, 7 :72
[4]  
Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
[5]   Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure? [J].
Adam, Rene ;
Wicherts, Dennis A. ;
de Haas, Robbert J. ;
Ciacio, Oriana ;
Levi, Francis ;
Paule, Bernard ;
Ducreux, Michel ;
Azoulay, Daniel ;
Bismuth, Henri ;
Castaing, Denis .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1829-1835
[6]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[7]   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[8]  
AUNE S, 1972, SURG GYNECOL OBSTETR, V135, P727
[9]  
Belle S H, 1995, Clin Transpl, P19
[10]   Liver Resection for Metastatic Colorectal Cancer in the Presence of Extrahepatic Disease [J].
Carpizo, Darren R. ;
D'Angelica, Michael .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (09) :2411-2421